Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei-Fei Tang

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|April 27, 2024
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapyFei-Fei Tang, Wen-Bing Duan, Xiao-Hong Liu, et al.
Scientific Reports|February 13, 2020
Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidatesLe-Qing Cao, Meng Lv, Lan-Ping Xu, et al.
Journal of Hematology & Oncology|July 6, 2017
Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysisYing-Jun Chang, Yu Wang, Yan-Rong Liu, et al.
Journal of Hematology & Oncology|April 2, 2020
Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized studyYing-Jun Chang, Yu Wang, Lan-Ping Xu, et al.
Bone Marrow Transplantation|May 10, 2020
Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibodyYing-Jun Chang, Lan-Ping Xu, Yu Wang, et al.
Leukemia & Lymphoma|February 10, 2016
Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantationYing-Jun Chang, Hong-Tao Wang, Lan-Ping Xu, et al.
Cellular & Molecular Immunology|January 7, 2021
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantationHuidong Guo, Ying-Jun Chang, Yan Hong, et al.
Bone Marrow Transplantation|August 23, 2025
Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective studySi-Qi Li, Lan-Ping Xu, Yu Wang, et al.
Bone Marrow Transplantation|April 11, 2023
Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantationZheng-Li Xu, Lan-Ping Xu, Yuan-Yuan Zhang, et al.
Clinical Transplantation|November 22, 2020
The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemiaZheng-Li Xu, Yi-Fei Cheng, Yuan-Yuan Zhang, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|April 27, 2024
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapyFei-Fei Tang, Wen-Bing Duan, Xiao-Hong Liu, et al.
Scientific Reports|February 13, 2020
Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidatesLe-Qing Cao, Meng Lv, Lan-Ping Xu, et al.
Journal of Hematology & Oncology|July 6, 2017
Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysisYing-Jun Chang, Yu Wang, Yan-Rong Liu, et al.
Journal of Hematology & Oncology|April 2, 2020
Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized studyYing-Jun Chang, Yu Wang, Lan-Ping Xu, et al.
Bone Marrow Transplantation|May 10, 2020
Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibodyYing-Jun Chang, Lan-Ping Xu, Yu Wang, et al.
Leukemia & Lymphoma|February 10, 2016
Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantationYing-Jun Chang, Hong-Tao Wang, Lan-Ping Xu, et al.
Cellular & Molecular Immunology|January 7, 2021
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantationHuidong Guo, Ying-Jun Chang, Yan Hong, et al.
Bone Marrow Transplantation|August 23, 2025
Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective studySi-Qi Li, Lan-Ping Xu, Yu Wang, et al.
Bone Marrow Transplantation|April 11, 2023
Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantationZheng-Li Xu, Lan-Ping Xu, Yuan-Yuan Zhang, et al.
Clinical Transplantation|November 22, 2020
The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemiaZheng-Li Xu, Yi-Fei Cheng, Yuan-Yuan Zhang, et al.
Pageof 6